Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Current Leases (2019 - 2026)

Summit Therapeutics filings provide 8 years of Current Leases readings, the most recent being $3.2 million for Q1 2026.

  • Quarterly Current Leases fell 10.27% to $3.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.2 million through Mar 2026, down 10.27% year-over-year, with the annual reading at $3.4 million for FY2025, 10.01% down from the prior year.
  • Current Leases hit $3.2 million in Q1 2026 for Summit Therapeutics, down from $3.4 million in the prior quarter.
  • Across five years, Current Leases topped out at $3.8 million in Q3 2024 and bottomed at $684000.0 in Q2 2022.
  • Average Current Leases over 5 years is $2.7 million, with a median of $2.9 million recorded in 2023.
  • The largest annual shift saw Current Leases crashed 32.01% in 2022 before it soared 328.07% in 2023.
  • Summit Therapeutics' Current Leases stood at $1.7 million in 2022, then surged by 66.21% to $2.8 million in 2023, then skyrocketed by 34.03% to $3.8 million in 2024, then fell by 10.01% to $3.4 million in 2025, then fell by 6.17% to $3.2 million in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Current Leases are $3.2 million (Q1 2026), $3.4 million (Q4 2025), and $2.7 million (Q3 2025).